


miREIA
miRNA Enzyme Immunoassay



microRNAs for Diagnostics in **Cardiovascular Disease**



microRNAs (miRNAs) are a class of single-stranded non-coding RNA molecules with a length of 19-23 nucleotides. They play a role in negative post-transcriptional regulation by binding to complementary sequences on mRNA and blocking translation into protein. miRNA not only regulate functions in the healthy heart but also play a role in mechanisms of cardiovascular disease.

miRNA can be released into biological fluids, including blood, from dying cells, such as necrotic cardiomyocytes following AMI, or actively secreted from living cells under stimulation.

miRNA show a high degree of stability in circulation and withstand conditions such as long-term storage, multiple freeze/thaw cycles and different pH, which makes them ideal biomarkers.



QUANTITATIVE

- Sensitive
- Absolute quantification



ROBUST

- ELISA platform
- No reverse transcription
- No amplification



FAST

- 2-hours assay



AFFORDABLE


- Low cost per sample
- No special equipment

Circulating microRNAs associated with the diagnosis of various CVDs

Chronic heart failure			
miRNA	Direction of alteration	Value of biomarker	References
miR-22	Increased	Diagnostic	5
miR-30c	Decreased	Diagnostic	6
miR-92b	Increased	Diagnostic	5
miR-107	Decreased	Diagnostic	7
miR-122	Increased	Diagnostic	8
miR-126	Increased	Prognostic	11
miR-139	Decreased	Diagnostic	7
miR-142-5p	Decreased	Diagnostic	7
miR-146a	Decreased	Diagnostic	6
miR-183-3p	Decreased	Diagnostic	9
miR-190a	Decreased	Diagnostic	9
miR-193b-3p	Decreased	Diagnostic	9
miR-193b-5p	Decreased	Diagnostic	9
miR-203	Decreased	Diagnostic	10
miR-210	Increased	Diagnostic	10
miR-211-5p	Decreased	Diagnostic	9
miR-221	Decreased	Diagnostic	6
miR-320a	Increased	Diagnostic	5
miR-328	Decreased	Diagnostic	6
miR-375	Decreased	Diagnostic	6
	Increased	Diagnostic	10
miR-423-5p	Increased	Diagnostic	5
miR-494	Decreased	Diagnostic	9
miR-508-5p	Increased	Prognostic	11
miR-520d-5p	Increased	Diagnostic	8
miR-558	Decreased	Diagnostic	8
miR-671-5p	Increased	Diagnostic	9
miR-1180	Increased	Diagnostic	10
miR-1233	Increased	Diagnostic	9
miR-1908	Increased	Diagnostic	10

Coronary artery disease			
miRNA	Direction of alteration compared with controls	Value of biomarker	References
miR-17	Decreased	Diagnostics	31
miR-19a	Decreased	Diagnostics	32
miR-29a	Decreased	Diagnostics	32
miR-30e-5p	Decreased	Diagnostics	32
miR-126	Decreased	Diagnostics	31
miR-133	Increased	Diagnostics	31
miR-145	Decreased	Diagnostics	31, 32
miR-146	Increased	Diagnostic/Prognostic	33
miR-150	Decreased	Diagnostics	32
miR-155	Decreased	Diagnostics	32
miR-182	Increased	Diagnostics	34
miR-208a	Increased	Diagnostics	31
miR-221	Increased	Diagnostics	35
miR-222	Increased	Diagnostics	32
miR-342	Decreased	Diagnostics	32
miR-378	Decreased	Diagnostics	32
miR-484	Decreased	Diagnostics	32

Stable angina pectoris			
miRNA	Direction of alteration compared with controls	Value of biomarker	References
mR-1	Increased	Diagnostic	36
miR-126	Decreased	Diagnostic	36
miR-133	Increased	Diagnostic	31
miR-147	Decreased	Diagnostic	37
miR-199a	Decreased in future cardiovascular events	Prognostic	38
miR-485-3p	Increased	Diagnostic	36



Unstable angina pectoris			
miRNA	Direction of alteration compared with stable angina pectoris and controls	Value of biomarker	References
miR-21	Increased	Diagnostic	39
miR-25	Increased	Diagnostic	39
miR-92a	Decreased	Diagnostic	39
miR-106b	Increased	Diagnostic	39
miR-126	Increased	Diagnostic	39
miR-590-5p	Increased	Diagnostic	39

Myocardial infarction			
miRNA	Direction of alteration compared with controls	Value of biomarker	References
miR-1	Increased	Diagnostic/Prognostic	15, 16, 17, 18
miR-21-5p	Increased	Diagnostic	19
miR-26a-5p	Decreased	Diagnostic	20
miR-30a	Increased	Diagnostic	21
miR-92a	Increased	Diagnostic	22
miR-122	Decreased	Diagnostic	23
miR-126-3p	Decreased	Diagnostic	20
miR-133a	Increased	Diagnostic	16, 18, 19, 24, 25, 26
miR-150-3p	Increased	Diagnostic	20
miR-191-5p	Decreased	Diagnostic	20
miR-208a/b	Increased	Diagnostic/Prognostic	4, 16, 28, 29
miR-328	Increased	Diagnostic	24
miR-375	Decreased	Diagnostic	23
miR-423-5p	Increased	Diagnostic	19
miR-486-3p	Increased	Diagnostics	20
miR-499	Increased	Diagnostics	4, 16, 29, 30

Acute heart failure			
miRNA	Direction of alteration	Value of biomarker	References
miR-18a-5p	Decreased	Diagnostic/Prognostic	1
miR-26b-5p	Decreased	Diagnostic	1
miR-27a-3p	Decreased	Diagnostic	1
miR-30b	Decreased	Diagnostic	2
miR-30e-5p	Decreased	Diagnostic	1
miR-103	Decreased	Diagnostic	2
miR-106a-5p	Decreased	Diagnostic	1
miR-142-3p	Decreased	Diagnostic	2
miR-199a-3p	Decreased	Diagnostic	1
miR-342-3p	Decreased	Diagnostic	2
miR-423-5p	Increased	Diagnostic	3
miR-499	Increased	Diagnostic	4
miR-652-3p	Decreased	Diagnostic/Prognostic	1

Circulating microRNAs associated with the response to therapy in heart failure patients		
miRNA	Direction of alteration compared with controls	References
miR-1	Increased	10
miR-26b-5p	Decreased	12
miR-29a-3p	Decreased	12
miR-30d	Increased	13
miR-30e-5p	Decreased	12
miR-92a-3p	Decreased	12
miR-145-5p	Decreased	10
miR-208a/208b	Increased	10
miR-483-3p	Increased	14
miR-499	Increased	10
miR-1202	Increased	14

REFERENCES

1. Ovchinnikova, Ekaterina S., et al. Signature of circulating microRNAs in patients with acute heart failure. *European journal of heart failure* 18.4 (2016): 414-423.
2. Ellis, Katrina L., et al. Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. *European journal of heart failure* 15.10 (2013): 1138-1147.
3. Tijssen, Anke J., et al. MiR423-5p as a circulating biomarker for heart failure. *Circulation research* 106.6 (2010): 1035-1039.
4. Corsten, Maarten F., et al. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. *Circulation: Genomic and Precision Medicine* (2010): CIRCGENETICS-110.
5. Goren, Yaron, et al. Serum levels of microRNAs in patients with heart failure. *European journal of heart failure* 14.2 (2012): 147-154.
6. Meder, Benjamin, et al. MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. *Basic research in cardiology* 106.1 (2011): 13-23.
7. Voellenkle, Christine, et al. MicroRNA signatures in peripheral blood mononuclear cells of chronic heart failure patients. *Physiological genomics* 42.3 (2010): 420-426.
8. Vogel, Britta, et al. Multivariate miRNA signatures as biomarkers for non-ischaemic systolic heart failure. *European heart journal* 34.36 (2013): 2812-2823.
9. Wong, Lee Lee, et al. Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction. *European journal of heart failure* 17.4 (2015): 393-404.
10. Akat, Kemal Marc, et al. Comparative RNA-sequencing analysis of myocardial and circulating small RNAs in human heart failure and their utility as biomarkers. *Proceedings of the National Academy of Sciences* 111.30 (2014): 11151-11156.
11. Qiang, Liu, et al. Expression of miR-126 and miR-508-5p in endothelial progenitor cells is associated with the prognosis of chronic heart failure patients. *International journal of cardiology* 168.3 (2013): 2082-2088.
12. Marfella, Raffaele, et al. Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders. *European journal of heart failure* 15.11 (2013): 1277-1288.
13. Melman, Yonathan F., et al. Circulating MicroRNA-30d is associated with response to cardiac resynchronization therapy in heart failure and regulates cardiomyocyte apoptosis: a translational pilot study. *Circulation* (2015): CIRCULATIONAHA-114.
14. Morley-Smith, Andrew C., et al. Circulating microRNAs for predicting and monitoring response to mechanical circulatory support from a left ventricular assist device. *European journal of heart failure* 16.8 (2014): 871-879.
15. Ai, Jing, et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. *Biochemical and biophysical research communications* 391.1 (2010): 73-77.
16. Wang, Guo-Kun, et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. *European heart journal* 31.6 (2010): 659-666.
17. Gidlöf, Olof, et al. Circulating cardio-enriched microRNAs are associated with long-term prognosis following myocardial infarction. *BMC cardiovascular disorders* 13.1 (2013): 12.
18. Gidlöf, Olof, et al. Cardiospecific microRNA plasma levels correlate with troponin and cardiac function in patients with ST elevation myocardial infarction, are selectively dependent on renal elimination, and can be detected in urine samples. *Cardiology* 118.4 (2011): 217-226.
19. Olivieri, Fabiola, et al. Diagnostic potential of circulating miR-499-5p in elderly patients with acute non ST-elevation myocardial infarction. *International journal of cardiology* 167.2 (2013): 531-536.
20. Hsu, An, et al. Systemic approach to identify serum microRNAs as potential biomarkers for acute myocardial infarction. *BioMed research international* 2014 (2014).
21. Long, Guangwen, et al. Circulating miR-30a, miR-195 and let-7b associated with acute myocardial infarction. *PLoS one* 7.12 (2012): e50926.
22. De Rosa, Salvatore, et al. Transcoronary Concentration Gradients of Circulating MicroRNAs Clinical Perspective. *Circulation* 124.18 (2011): 1936-1944.
23. D'Alessandra, Yuri, et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. *European heart journal* 31.22 (2010): 2765-2773.
24. Wang, Rongrong, et al. Circulating microRNAs are promising novel biomarkers of acute myocardial infarction. *Internal Medicine* 50.17 (2011): 1789-1795.
25. Li, Ying-Qing, et al. Comparing the diagnostic values of circulating microRNAs and cardiac troponin T in patients with acute myocardial infarction. *Clinics* 68.1 (2013): 75-80.
26. Peng, Liu, et al. Clinical impact of circulating miR-133, miR-1291 and miR-663b in plasma of patients with acute myocardial infarction. *Diagnostic pathology* 9.1 (2014): 89.
27. Widera, Christian, et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. *Journal of molecular and cellular cardiology* 51.5 (2011): 872-875.
28. Devaux, Yvan, et al. Use of circulating microRNAs to diagnose acute myocardial infarction. *Clinical chemistry* 58.3 (2012): 559-567.
29. Adachi, Taichi, et al. Plasma microRNA 499 as a biomarker of acute myocardial infarction. *Clinical chemistry* 56.7 (2010): 1183-1185.
30. Fichtlscherer, Stephan, et al. Circulating microRNAs in patients with coronary artery disease: novelty and significance. *Circulation research* 107.5 (2010): 677-684.
31. Weber, Martina, et al. MicroRNA expression profile in CAD patients and the impact of ACEI/ARB. *Cardiology research and practice* 2011 (2011).
32. Takahashi, Yuji, et al. Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in coronary artery disease: effect of renin-angiotensin system blockade and statins on miRNA-146a/b and Toll-like receptor 4 levels. *Clinical Science* 119.9 (2010): 395-405.
33. Taurino, Chiara, et al. Gene expression profiling in whole blood of patients with coronary artery disease. *Clinical science* 119.8 (2010): 335-343.
34. Minami, Y., et al. Effect of atorvastatin on microRNA 221/222 expression in endothelial progenitor cells obtained from patients with coronary artery disease. *European journal of clinical investigation* 39.5 (2009): 359-367.
35. D'Alessandra, Yuri, et al. Diagnostic potential of plasmatic MicroRNA signatures in stable and unstable angina. *PLoS one* 8.11 (2013): e80345.
36. Hoekstra, Menno, et al. The peripheral blood mononuclear cell microRNA signature of coronary artery disease. *Biochemical and biophysical research communications* 394.3 (2010): 792-797.
37. Jansen, Felix, et al. MicroRNA expression in circulating microvesicles predicts cardiovascular events in patients with coronary artery disease. *Journal of the American Heart Association* 3.6 (2014): e001249.
38. Ren, Jingyi, et al. Signature of circulating microRNAs as potential biomarkers in vulnerable coronary artery disease. *PLoS one* 8.12 (2013): e80738.

Date of issue February 2018

Contact Information



BioVendor – Laboratorní medicína a.s.

Karasek 1767/1, 621 00 Brno, Czech Republic
Phone: +420 549 124 185, Fax: +420 549 211 460
E-mail: info@biovendor.com

BioVendor GmbH

Otto-Hahn-Straße 16, 34123 Kassel, Germany
Phone: +49 (0)561 861 509 33, Fax: +49 (0)561 861 509 34
E-mail: infoEU@biovendor.com

› www.biovendor.com



BioVendor GesmbH

Gaudenzdorfer Gürtel 43-45, 1120 Vienna, Austria
Phone: +43 1 890 9025, Fax: +43 1 890 5163
E-mail: infoAustria@biovendor.com

BioVendor, LLC

128 Bingham Rd., Suite 1300, Asheville, NC 28806, USA
Phone: +1-800-404-7807, Phone: +1-828-575-9250
Fax: +1-828-575-9251, E-mail: infoUSA@biovendor.com



Oxford Biosystems Ltd

184B Park House, Park Drive,
Milton Park, Abingdon, Oxfordshire
OX14 4SR, United Kingdom
Phone: +44 (0)1235 431390
E-mail: sales@oxfordbiosystems.com

› www.oxfordbiosystems.com